Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Friday, Canaccord Genuity maintained its Buy rating on Natera (NASDAQ:NTRA) shares and increased its price target to $195, up from the previous $180. The adjustment comes after Natera’s fourth-quarter results for 2024, which surpassed the company’s preliminary estimates announced in January 2025. The results were released on Thursday, February 27, and showed a slight outperformance, marking another strong quarter for the genetic testing company. With a market capitalization of $20.7 billion and impressive revenue growth of 54.9% over the last twelve months, Natera has demonstrated robust business expansion. InvestingPro data reveals three analysts have recently revised their earnings estimates upward for the upcoming period.
The company’s success in the fourth quarter was attributed to significant growth in test volumes across its three main business segments. This increase was supported by a solid average selling price and one-time financial adjustments. Notably, Natera achieved positive operating cash flows for the fourth consecutive quarter, indicating a consistent financial performance. The company maintains a strong liquidity position with a current ratio of 4.39, while operating with a moderate debt level. For deeper insights into Natera’s financial health and 10+ additional ProTips, consider accessing the comprehensive research available on InvestingPro.
Canaccord Genuity’s analysts are optimistic about Natera’s future, especially in light of the company’s initial guidance for 2025. The guidance suggests a year-over-year revenue growth in the mid-20% range, with expectations of continued strong gross margins and positive cash flow. The firm’s confidence in Natera is further bolstered by potential benefits from likely improved Medicare Advantage rates and biomarker legislation expected in 2025.
The research firm’s bullish stance on Natera is also based on the company’s valuation. Canaccord Genuity believes that Natera’s stock remains undervalued and sees significant upside potential to their discounted cash flow (DCF)-based price target. This reassessment of the price target reflects the firm’s upward revisions of estimates following Natera’s fourth-quarter performance. The stock has delivered an impressive 104.6% return over the past year, though InvestingPro’s Fair Value analysis suggests the stock is currently trading above its intrinsic value. Analyst targets for the stock range from $37 to $210, reflecting diverse market opinions on the company’s prospects.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, exceeding Wall Street expectations with a narrower-than-anticipated loss per share and higher revenue. The company posted an earnings per share (EPS) of -$0.41, surpassing the forecasted -$0.49, and achieved revenue of $476 million, significantly beating the predicted $409.89 million. This represents a 53% year-over-year increase in revenue, driven by strong demand for its Signatera product and advancements in molecular diagnostics. Despite these strong financial results, Natera’s stock fell 2.46% during regular trading hours. Looking ahead, Natera has set its 2025 revenue guidance between $1.87 billion and $1.95 billion, indicating a 24% growth at the midpoint. The company plans to continue investing in research and development, particularly in molecular residual disease (MRD) and early cancer detection. Additionally, Natera aims to expand its reimbursement strategies and payer coverage to enhance revenue per test. Analyst firm Wolfe Research participated in the earnings call, where discussions included the company’s efforts to improve average selling prices and reimbursement rates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.